The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
21-Nov-11
$689 million
Target:
iNova Pharmaceuticals
Acquiror:
Valeant Pharmaceuticals
Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals
28-Jun-16
$652 million
Target:
US rights to 37 approved and 5 pipeline generic products
Acquiror:
Mayne Pharma Group Limited
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
22-Jun-15
$640 million
Target:
28-property portfolio of independent living senior housing properties from affiliates of Holiday Retirement, an entity controlled by Fortress Investment Group
Acquiror:
New Senior Investment Group Inc.
Provided Fairness Opinion to the Transaction Committee of the Board of Directors of New Senior Investment Group, a $2.5 billion publicly traded REIT, on its acquisition of a 28-property portfolio from Holiday Retirement, one of the largest private operators of senior housing in the US
04-Oct-23
$610 million
Target:
Lucky Bucks, LLC
Advised the Term Loan Ad Hoc Group to Lucky Bucks, one of the largest Class B coin operated amusement machine (“COAM”) route operators in Georgia, on Lucky Bucks’ financial restructuring and chapter 11 process
30-Jun-11
$609 million
Target:
Diabetes-related patent estate and royalty stream of Astellas Pharma subsidiary, Prosidion
Acquiror:
Royalty Pharma
Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion
13-Mar-24
$590 million (AUD value)
Target:
Liontown Resources Limited
Advised Australian-based lithium company Liontown Resources Limited on its A$590m debt facility to fund the Kathleen Valley Lithium Project
21-Jun-16
$586 million
Target:
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Impax Laboratories, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
10-Jun-10
$580 million
Target:
Tishman Speyer Washington D.C. Portfolio
Advised term loan and credit facility lenders to the Tishman Speyer partnership holding a portfolio of 28 office buildings in Washington D.C. and the surrounding area on a restructuring which resulted in payoff of the facilities in full
10-Mar-10
$576 million
Target:
Camelot Group plc
Acquiror:
Ontario Teachers’ Pensions Plan
Advised the shareholders of Camelot – Cadbury, De La Rue, Fujitsu, Royal Mail and Thales – on the sale of their shareholdings in Camelot, the operator of the UK National Lottery, to Ontario Teachers’ Pensions Plan
02-May-19
$545 million
Target:
Kidman Resources Limited
Acquiror:
Wesfarmers
Advised Kidman Resources, an ASX-listed hard rock lithium mining company, on its sale to Wesfarmers, one of Australia’s largest diversified listed companies
14-Jan-20
$537 million
Target:
Hycroft Mining Corporation
Acquiror:
Mudrick Capital Acquisition Corporation
Advised Hycroft Mining Corporation, a US-based, gold and silver producer operating the Hycroft mine located in Northern Nevada, on the sale of substantially all of its assets to Mudrick Capital Acquisition Corporation
26-Mar-12
$513 million
Target:
ISTA Pharmaceuticals, Inc.
Acquiror:
Bausch + Lomb, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its sale to Bausch + Lomb, Inc., a global ophthalmic products company
07-Dec-10
$500 million
Target:
Medicity, Inc.
Acquiror:
Aetna Inc.
Advised Aetna Inc. on its acquisition of Medicity, Inc., a leading provider of technology solutions to enable the secure access and exchange of healthcare information
09-Jan-17
$465 million
Target:
Palatin Technologies, Inc. lead product candidate, Rekynda
Acquiror:
AMAG Pharmaceuticals, Inc.
Advised Palatin Technologies, Inc. on the exclusive licensing of North American rights to develop and commercialize RekyndaTM (bremelanotide), an investigational product designed for on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, to AMAG Pharmaceuticals, Inc.
08-Oct-09
$455 million
Target:
Ladbrokes Plc
Acted as Joint Financial Adviser to Ladbrokes plc, a leading UK based betting and gaming company, on its rights issue
07-Jul-23
Pending
$439 million
Target:
Australian Unity Diversified Property Fund
Acquiror:
Cromwell Direct Property Fund
Advising Australian Unity Property Limited, as the responsible entity of the Australian Unity Diversified Property Fund, on Australian Unity Diversified Property Fund’s merger with Cromwell Direct Property Fund
10-Feb-23
Pending
$415 million
Target:
Gaming Services Division of Global Payments
Acquiror:
Parthenon Capital
Advising Parthenon Capital, a financial services & technology focused private equity firm, on its acquisition of Global Payment’s Gaming Services Division, a leading provider of on-site and digital payment processing services to companies in the gaming industry, for $415mm
15-Jun-16
$414 million
Target:
Aegerion Pharmaceuticals
Acquiror:
QLT Inc.
Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization
01-Nov-21
$400 million
Target:
Millennial Lithium
Acquiror:
Lithium Americas
Advised Lithium Americas, a development-stage company with projects in Jujuy, Argentina and Nevada, United States on its acquisition of Millennial Lithium, a Vancouver-based exploration and development company focused on advancing the Pastos Grandes Lithium Project in Argentina
07-Nov-11
$398 million
Target:
American Dental Partners, Inc.
Acquiror:
JLL Partners
Advised American Dental Partners, Inc. (NASD: ADPI), one of the nation’s leading business partners to dental group practices, on its sale to JLL Partners, a leading private equity firm
23-Sep-10
$394 million
Target:
Aevum Ltd.
Acquiror:
Stockland Corp. Ltd
Advised Aevum Limited, an ASX listed owner, operator and developer of retirement villages and aged care facilities on its response to a hostile takeover offer from Stockland Ltd, a global property development and investment management group
19-Oct-23
$390 million (AUD value)
Target:
Liontown Resources Limited
Advised Australian-based lithium company Liontown Resources Limited on its A$390m equity raising to fund the Kathleen Valley Lithium Project
22-Jan-18
$375 million
Target:
Lonmin
Advising Lonmin PLC, a major fully integrated producer of Platinum Group Metals, on the amendment of its debt facilities to support the review and implementation of its strategic options
01-Dec-21
$353 million
Target:
Liontown Resources
Acquiror:
N/A
Advised Liontown Resources, an ASX-listed lithium company focused on the development of the world class Kathleen Valley Lithium Project, on its A$490m equity raising, comprised of a fully underwritten placement of A$450m and a non-underwritten share purchase plan of A$40m
11-Jun-16
$350 million
Target:
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Dr. Reddy’s Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories